Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Mar;9(3):454-8.
doi: 10.3748/wjg.v9.i3.454.

Effects of tachyplesin on the regulation of cell cycle in human hepatocarcinoma SMMC-7721 cells

Qi-Fu Li  1 , Gao-Liang Ou-Yang, Xuan-Xian Peng, Shui-Gen Hong
Affiliations

Effects of tachyplesin on the regulation of cell cycle in human hepatocarcinoma SMMC-7721 cells

Qi-Fu Li et al. World J Gastroenterol. 2003 Mar.

Abstract

Aim: To investigate the effects of tachyplesin on the cell cycle regulation in human hepatcarcinoma cells.

Methods: Effects of tachyplesin on the cell cycle in human hepatocarcinoma SMMC-7721 cells were assayed with flow cytometry. The protein levels of p53, p16, cyclin D1 and CDK4 were assayed by immunocytochemistry. The mRNA levels of p21(WAF1/CIP1) and c-myc genes were examined with in situ hybridization assay.

Results: After tachyplesin treatment, the cell cycle arrested at G0/G1 phase, the protein levels of mutant p53, cyclin D1 and CDK4 and the mRNA level of c-myc gene were decreased, whereas the levels of p16 protein and p21(WAF1/CIP1) mRNA increased.

Conclusion: Tachyplesin might arrest the cell at G0/G1 phase by upregulating the levels of p16 protein and p21(WAF1/CIP1) mRNA and downregulating the levels of mutant p53, cyclin D1 and CDK4 proteins and c-myc mRNA, and induce the differentiation of human hepatocacinoma cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Immunocytochemistry analysis of the effects of tachyplesin on the protein levels of mutant p53, p16, cyclin D1, CDK4 in SMMC-7721 cells ( × 536). The protein levels of mutant p53 (A), cyclin D1 (E), CDK4 (G) were high in SMMC-7721 cells while the levels of mutant p53 (B), cyclin D1 (F), CDK4 (H) were decreased by tachyplesin. The level of p16 protein was low in SMMC-7721 cells (C) while high in the tachyplesin-treated cells (D).
Figure 2
Figure 2
In situ hybridization analysis of p21WAF1/CIP1 and c-myc mRNA in untreated and tachyplesin-treated SMMC-7721 cells ( × 536). The level of p21WAF1/CIP1 mRNA was low in SMMC-7721 cells (A) but high in the tachyplesin-treated cells (B). High level of c-myc mRNA was observed in SMMC-7721 cells (C) while the level of c-myc mRNA in the tachyplesin-treated cells down-regulated (D).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yoneda K, Yamamoto T, Ueta E, Osaki T. Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells. Cancer Lett. 1998;133:35–45. - PubMed
    1. Lo Coco F, Zelent A, Kimchi A, Carducci M, Gore SD, Waxman S. Progress in differentiation induction as a treatment for acute promyelocytic leukemia and beyond. Cancer Res. 2002;62:5618–5621. - PubMed
    1. Wang Z, Sun G, Shen Z, Chen S, Chen Z. Differentiation therapy for acute promyelocytic leukemia with all-trans retinoic acid: 10-year experience of its clinical application. Chin Med J (Engl) 1999;112:963–967. - PubMed
    1. Leszczyniecka M, Roberts T, Dent P, Grant S, Fisher PB. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther. 2001;90:105–156. - PubMed
    1. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis. 2000;21:1271–1279. - PubMed

Publication types

MeSH terms

Substances